Medical Lecture: Pulmonary Embolism in Pregnancy

Pulmonary Embolism in Pregnancy

Comprehensive Clinical Lecture: Epidemiology, Diagnosis, and Management

1. Epidemiology & Incidence

Pulmonary Embolism (PE) is the leading cause of direct maternal mortality in the developed world.

• Incidence: Approximately 1 to 2 cases per 1,000 pregnancies.
• Mortality Risk: The risk of death from PE is significantly higher in pregnant women compared to non-pregnant women of childbearing age.
• Timing:
  • Antepartum: 60% of cases occur before delivery.
  • Postpartum: 40% occur after delivery (highest risk in the first week).

Why the increased risk? Pregnancy is a state of hypercoagulability. Factors include increased clotting factors (VII, VIII, X, Fibrinogen), decreased Protein S, and venous stasis due to uterine compression of the iliac veins.

2. Risk Factors & Onset

Risk Factors (Virchow's Triad)

• Maternal Age: Risk increases significantly with age (>35 years).
• Obesity: BMI > 30 kg/m².
• History: Previous VTE (Venous Thromboembolism) or family history of thrombophilia.
• Immobility: Prolonged bed rest, hospitalization.
• Assisted Reproduction: IVF pregnancies carry a slightly higher risk.
• Smoking: Increases coagulability.

Onset

Onset can be sudden (acute massive PE) or insidious (submassive). Symptoms often appear abruptly during the second or third trimester or immediately postpartum.

3. Signs & Symptoms

Diagnosis is challenging because normal physiological changes of pregnancy mimic PE symptoms.

Symptom	Normal Pregnancy vs. PE
Dyspnea	Common in pregnancy. Sudden onset or worsening suggests PE.
Tachycardia	Heart rate increases in pregnancy (up to 100 bpm). >100-110 bpm is suspicious.
Chest Pain	Pleuritic (sharp, worse on breathing) is highly specific for PE.
Leg Symptoms	Unilateral leg swelling, pain, or warmth (DVT signs).
Hemoptysis	Coughing up blood (rare but specific).

Clinical Pearl: If a pregnant woman presents with sudden unexplained shortness of breath or syncope, PE must be ruled out until proven otherwise.

4. Investigation & Diagnosis

Step 1: Clinical Assessment

Use of scoring systems (e.g., Wells Score), though less validated in pregnancy, helps stratify risk.

Step 2: D-Dimer

Limitation: D-dimer levels naturally rise during pregnancy. A negative D-dimer is useful to rule out PE, but a positive D-dimer is non-specific and does not confirm PE.

Step 3: Imaging

• ECG: Often shows sinus tachycardia. S1Q3T3 pattern is rare.
• Chest X-Ray: Usually normal, but rules out pneumonia/pneumothorax.
• Leg Doppler Ultrasound: If DVT is found, treat for PE without further chest imaging.
• CT Pulmonary Angiography (CTPA): Gold standard. Radiation dose to the breast is low. Safe for the fetus.
• V/Q Scan: Alternative if CTPA is contraindicated or renal failure exists. Lower radiation to breast, but slightly higher fetal radiation (though still safe).

5. Effects on Fetus & Pregnancy Safety

Maternal Impact

Maternal hypoxia and hemodynamic collapse (shock) are the primary threats. If the mother dies, the fetus usually cannot survive.

Fetal Impact

• Hypoxia: Maternal oxygen desaturation leads to fetal distress.
• Preterm Birth: Often necessitated by maternal instability or need for emergency delivery.
• Low Birth Weight: Associated with chronic placental insufficiency if recurrent micro-emboli occur.
• Intrauterine Growth Restriction (IUGR): Possible complication.

6. Treatment

Acute Management

1. Stabilization: Oxygen therapy to maintain saturation >95%. IV fluids (cautiously).
2. Anticoagulation (Gold Standard):
   • LMWH (Low Molecular Weight Heparin): Enoxaparin is preferred. It does not cross the placenta and is safe for the fetus.
   • Unfractionated Heparin (UFH): Used if delivery is imminent (short half-life, reversible with Protamine).
3. Thrombolysis: Reserved for massive PE with hemodynamic instability (shock/hypotension). High risk of bleeding but life-saving.

Medications to AVOID

• Warfarin: Teratogenic (causes warfarin embryopathy) in the first trimester and risk of fetal bleeding later.
• DOACs (e.g., Rivaroxaban): Generally not recommended due to lack of safety data in pregnancy.

7. Mode of Delivery

Vaginal delivery is generally preferred over Cesarean section to reduce bleeding risks and recovery time.

Anticoagulation Management during Labor

• Planned Induction/C-Section: Stop LMWH 24 hours prior to the procedure to allow for epidural/spinal anesthesia (reduces risk of spinal hematoma).
• Spontaneous Labor: If on therapeutic LMWH, epidural may be contraindicated. General anesthesia or systemic opioids may be required.
• Postpartum: Resume anticoagulation 4-6 hours after vaginal delivery or 6-12 hours after C-section, once hemostasis is secured.

8. Prevention & Lifestyle Modification

Prevention is key, especially for high-risk women (previous VTE, thrombophilia).

Pharmacological Prophylaxis

Prophylactic dose LMWH is prescribed for women with high-risk factors throughout pregnancy and for 6 weeks postpartum.

Lifestyle Modifications

• Hydration: Maintain adequate fluid intake to prevent hemoconcentration.
• Mobility: Avoid prolonged immobility. Walk frequently during long car rides or flights (>4 hours).
• Compression Stockings: Graduated compression stockings (Class I or II) help reduce venous stasis in the legs.
• Weight Management: Achieving a healthy weight before conception reduces baseline risk.
• Smoking Cessation: Critical for reducing cardiovascular and clotting risks.
• Leg Exercises: Ankle pump exercises when sitting for long periods.

© 2026 Medical Lecture Series. For educational purposes only.